Chronic hepatitis D—What is changing?

Hepatitis D virus (HDV) infection is a chronic viral disease of the liver that is still largely considered to be incurable due to lack of effective treatment options. Without treatment, the risk for the development of advanced liver disease, cirrhosis and hepatocellular carcinoma is significantly hi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2022-04, Vol.29 (4), p.240-251
Main Authors: Yardeni, David, Heller, Theo, Koh, Christopher
Format: Article
Language:English
Subjects:
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Chronic infection
chronic liver disease
Cirrhosis
Clinical trials
Hepatitis
hepatitis D
Hepatitis D - drug therapy
Hepatitis D - epidemiology
Hepatitis D, Chronic - complications
Hepatitis D, Chronic - drug therapy
Hepatitis D, Chronic - epidemiology
Hepatitis Delta Virus
Hepatocellular carcinoma
Humans
Interferon
Lipopeptides
Liver cirrhosis
Liver diseases
Liver Neoplasms - drug therapy
treatment
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis D virus (HDV) infection is a chronic viral disease of the liver that is still largely considered to be incurable due to lack of effective treatment options. Without treatment, the risk for the development of advanced liver disease, cirrhosis and hepatocellular carcinoma is significantly high. Currently, new therapeutic options are emerging out of ongoing phase 3 clinical trials, promising a new hope of cure for this devastating liver infection. Recently, bulevirtide, a first in its class HDV entry inhibitor, has received conditional authorization of use from the European Medicines Agency (EMA) and was also submitted for approval in the United States. Other novel therapeutic options in clincal trials include interferon lambda, the prenylation inhibitor lonafarnib and nucleic acidic polymers (NAPs). This review describes all recent advances and ongoing changes to the field of HDV therpaeutics.
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13651